Insight into advancements in prostate cancer imaging using PSMA agents like gallium and F-18, their unique characteristics, and the considerations in choosing the right radiotracer for accurate detection.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.